News

08/14/2019 - View the list of TIMI presentations and sessions at the 2019 ESC HERE.

07/17/2019 - New Publication: Bach, Cannon, Giugliano et al., Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.

07/01/2019 - Now in Print: Murphy et al., Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. JAMA Cards 2019

03/15/2019 - Visit us at Booth 1028 at ACC.19 in New Orleans!  View our list of presentions here

02/21/2019 - New Publication: Zelniker et al.,Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.The Lancet 2019. 

01/24/2019 - New Publication: Wiviott et al., Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. NEJM 2019. 

01/15/2019 - New Publication: Scirica et al.,Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation 2019. 

11/05/2018 - Visit us at Booth 1621 at AHA 2018 in Chicago!  View our list of presentions here

10/03/2018 - New Publication: Bohula et al.,Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet 2018. 

09/20/2018 - New Publication: Bohula et al., Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. NEJM 2018.

09/01/2018 -  New Publication: Sabatine et al., Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis. JAMA Cards 2018.

01/23/2018 - New Publication: Bonaca et al., Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial . Circ 2018.

12/05/2017 - New Publication: Sabatine et al., Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 2017.

12/01/2017 - New Publication: Giugliano et al., Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA Cards 2017 .

11/30/2017 - New Publication: Cavallari et al., Frequency, Predictors and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients with Symptomatic Atherosclerosis. Circ 2017.

08/28/2017 -  Slide deck and paper for achieved very low LDL-C in FOURIER now available 

08/28/2017New Publication: Ference B et al., Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. 2017 Lancet.

03/17/2017 - FOURIER primary results slide deck and NEJM paper now available

03/12/2017 - TIMI Presentation Schedule See what TIMI Investigators are up to at ACC.17

03/14/2017 - New Publication: Koren MJ, Sabatine MS, Giugliano RP et al., Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. 2017 JAMA Cardiol.

02/01/2017 - New Publication: Giugliano RP et al., Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. 2017 Clin Cardiol.

11/12/2016 - AHA 2016 Scientific Sessions - TIMI Presentation Schedule

10/24/2016 - New Publication: Bonaca et al., Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial. 2016 JACC Cardiovasc Interv.

 09/27/2016 - New Publication: Silverman et al., Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. 2016 JAMA.

09/20/2016 - New Publication: Bonaca et al., Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54. 2016 Circ.

09/15/2016 - TIMI Risk Score for Secondary Prevention Calculator  -- now available

06/03/2015 - New Publication: Cannon et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. MORE

05/30/2015 - New Publication: O'Donoghue et al. Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. MORE

04/28/2015 - OSLER CV Outcomes Paper in NEJM recommended on F1000Prime MORE

04/28/2015 - VIDEO: PCSK9 Inhibitors: What to Know if They Come to Market MORE

03/24/2015 - VIDEO: New IMPROVE-IT analyses reinforce benefits of greater cholesterol reduction MORE

03/14/2015 - PEGASUS-TIMI 54 SLIDES AVAILABLE (pdf) MORE

03/14/2015 New Publication: Bonaca et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction MORE

03/05/2015 - TIMI presentations at ACC.15 MORE

03/04/2015  - Genetic Risk Linked to Clinical Benefit of Statin Therapy MORE

03/03/2015  - New Publication: Mega et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials MORE

01/26/2015 - Preliminary list of TIMI presentations at ACC.15 MORE

01/14/2015 - PEGASUS-TIMI 54 meets its primary endpoint. MORE

01/09/2015 - Edoxaban (Savaysa) studied in ENGAGE AF-TIMI 48 is approved by FDA. MORE

12/31/2014 - New Publication: Udell et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. MORE

12/23/2014 - New Publication: Bonaca et al. Prognostic performance of a high-sensitivity assay for cardiac troponin I after non-ST elevation acute coronary syndrome: Analysis from MERLIN-TIMI 36. MORE

12/09/2014 New Publication: Bonaca et al. New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial. MORE

12/09/2014 New Publication: Bonaca et al. Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 Trial. MORE

11/18/2014 -  IMPROVE IT-TIMI 40 Late Breaking Clinical Trial - Slides Available. MORE

11/14/2014 -  IMPROVE IT-TIMI 40 Late Breaking Clinical Trial at the American Heart Association Annual Meeting. MORE

11/12/2014 -  TIMI will present several abstracts at AHA 2014. PDF

11/14/2014 -  IMPROVE IT-TIMI 40 Late Breaking Clinical Trial at the American Heart Association Annual Meeting. MORE

11/12/2014 - TIMI will present several abstracts at AHA 2014. PDF

09/18/2014 - Today at 1pm, a special BWH Cardiovascular Grand Rounds – The TIMI Study Group: 30 Years of Cardiovascular Clinical Trials. Shapiro Building, 1st floor.

09/10/2014 - New Publication: O'Donoghue, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. MORE

09/04/2014 - New Publication: Scirica, et al. Heart Failure, Saxagliptin and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. MORE